Vaccine Info

GEO-LM01 Lassa Fever Vaccine

Authored by
Fact checked by
Robert Carlson, MD

GEO-LM01 Lassa Fever Vaccine Description

GEO-LM01 is a vaccine candidate that is based on the Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated.

VLPs mimic a natural infection, triggering the body to produce a robust and durable immune response with both antibodies and T cells.

GEO-LM01 Lassa Fever Vaccine Indication

GEO-LM01 is indicated to prevent Lassa Fever Infection

GEO-LM01 Lassa Fever Vaccine Dosage

This vaccine candidate has only been tested in mice.

GEO-LM01 Lassa Fever Vaccine News

September 4, 2019: GeoVax Labs announced the publication of its article entitled “A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge.”

Farshad Guirakhoo, Ph.D., GeoVax’s Chief Scientific Officer, commented, “GEO-LM01 uses GeoVax’s proven MVA-VLP vaccine platform that has been shown to be safe and to induce durable antibody and T-cell responses in multiple human clinical trials for GeoVax’s prophylactic HIV vaccine.

Using the same platform, we have shown our Zika vaccine (GEO-ZM02) provided single-dose 100% protection in mice against intracranial challenge, and that our Ebola vaccine (GEO-EM01) provided single-dose 100% protection in rhesus macaques.” It is remarkable that a replication-deficient vector can induce full protection after a single dose as soon as 2 weeks post-vaccination.

Clinical Trials

No clinical trials found